Phase 1 Study of a Self-amplifying RNA Vaccine (ITI-5000) in Stage 2-3 Triple Negative Breast Cancer

NCT07652242 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

60

Enrollment

INDUSTRY

Sponsor class

Conditions

Triple Negative Breast Cancer (TNBC)

Interventions

BIOLOGICAL: ITI-5000 mRNA Vaccine
DRUG: Pembrolizumab
BIOLOGICAL: ITI-5000 mRNA Vaccine
DRUG: Olaparib
DRUG: Capecitabine
BIOLOGICAL: ITI-5000 MTD (Maximum Tolerated Dose)

Sponsor

Immunomic Therapeutics, Inc.